Yahoo Finance's Kumutha Ramanathan has the latest from London.
Yahoo Finance's Kumutha Ramanathan has the latest from London.
Russian internet group Mail.ru on Monday reported a 19.9% rise in third-quarter revenue as lockdowns boosted gaming though growth slowed from the second quarter as restrictions eased. Mail.ru, which owns the popular Vkontakte and Odnoklassniki social networking websites, generates the bulk of its revenue from advertising and games. The London-listed company reported total revenue of 26.37 billion roubles ($344.90 million).
The former WWE champ said Trump's a pretend tough guy.
‘We do not get a chance at happiness’: the Bangladeshi fishermen caught by debt. Hilsa fishermen must borrow to buy equipment but have to sell their catch at a low price to moneylenders – creating a generational debt trap
Savosolar Plc Business review 26 October 2020 at 8.45 (CET) Savosolar Plc’s business review for January–September 2020: Revenue and profitability continued to develop favourably Key figures in July–September 2020 Savosolar’s revenue in July–September amounted to EUR 1.7 million (July–September 2019: EUR 0.1 million).Operating result (EBIT) amounted to EUR -0.8 million (EUR -1.3 million).Net result totalled EUR -1.0 million (EUR -1.3 million). Key figures in January–September 2020 Savosolar’s revenue in January–September amounted to EUR 3.7 million (January–September 2019: EUR 1.8 million).Operating result (EBIT) amounted to EUR -2.6 million (EUR -3.6 million).Net result for the period totalled EUR -3.5 million (EUR -4.6 million). Savosolar’s CEO Jari Varjotie: “Our business continued to develop favourably during the third quarter despite the Covid-19 pandemic, which we are very happy with. Our turnover in January-September doubled year-on-year. We were able to continue the ongoing client projects in Central Europe after the lifting of the restrictions imposed due to the Covid-19 pandemic in the early summer. In the third quarter, we signed an agreement on the delivery of a solar thermal system to the City of Narbonne in France. System is ordered by the same client, NewHeat SAS, for whom Savosolar already delivered a solar thermal system in Condat, France for the process heat generation of a paper mill in 2019. The new order serve as proof of our ability to deliver our customer promises. Our order backlog at the end of September stood at EUR 2.2 million (EUR 4.8 million). At the end of the reporting period, the order backlog was at a good level. The order backlog of the comparison period was increased by the signing of the Issoudun contract, the company’s larger order to date, in the early autumn of 2019. The value of our projects in the sales pipeline at the end of the reporting period was approximately EUR 279 million, being approximately EUR 260 million at the end of July. Of this, the total value of the projects in the tendering and planning stage amounted to approximately EUR 103 million (EUR 94 million at the end of June). The sales pipeline includes all the active projects entered in the company’s sales management system. The demand for renewable energy, and especially for genuinely clean, emission-free energy, continues to grow when the actions to curb climate change increase. According to the International Energy Agency (IEA), only the production of renewable energy continued to grow during the early part of the year despite the Covid-19 pandemic. Heat production accounted for more than 50% of the global energy production in 2019. According to the IEA, only 10% of this was produced with renewable energy. In Savosolar’s estimate, less than three per cent of the global thermal energy was produced with clean modes of energy production in 2019. In order to further step up its climate actions, the European Union has decided that 30% of its multi-annual budget and support instrument for recovery from the corona crisis for 2021-2023, totalling approximately EUR 1,800 billion, will be used for climate actions to strengthen the EU Green Deal programme. In our estimate, the Covid-19 pandemic has caused delays in the investment decisions of certain industrial customers. The Covid-19 situation and potential new restrictions may further postpone client investment decisions and deliveries, and we seek to prepare for the potential effects of the pandemic situation on our business. Our operating result for January–September was EUR -2.6 million. The net result for the reporting period also improved to EUR -1.0 million. The improved result was due to the increase in volume as well as the measures taken to improve our internal efficiency. We will continue our determined efforts to increase sales and to improve our internal efficiency towards profitable business. In line with our strategy, we have continued to build our international partner network. After the reporting period, in October, we signed an agreement with a German company named Citrinsolar GmbH on cooperation in the sale and delivery of large solar thermal systems in Germany. In October, we also signed a cooperation agreement on the representation of our products with a Polish company named Eko Ekon. Our objective is to conclude the first solar thermal system delivery contract to Poland during 2021. In Asia, cooperation with the Chinese company Guangzhou Power Supply Co., Ltd. advanced after the Covid delay in the spring. The objective is to build a renewable thermal energy system in Nansha, Guangzhou as part of the China-Finland Energy Programme. The project has advanced to the tendering stage, and if we win the competitive tendering, the objective is that an agreement is reached on the execution of the project during 2020. Savosolar is strongly committed to the fight against climate change by providing competitive and high-quality technology for the production of genuinely clean thermal energy on a large scale. Our strengths include advanced collector technology, strong references and ability to implement systems on a turnkey basis that exceed the client’s expectations. On the market, we are renowned as an innovative and dependable operator, who helps its clients to attain their environmental goals as cost-effectively as possible.” COMPARISON BY REPORTING PERIOD (FAS, unaudited) (EUR 1,000)Jul-Sep 2020Jul-Sep 2019Change (%)Jan-Sep 2020Jan-Sep 2019 Change (%)Jan-Dec 2019Revenue1 659961 624.23 7021 776108.53 415Operating profit/ loss (EBIT)-847 -1 25232.3 -2 564 -3 58428.5 -4 999Profit/loss for the period-969-1 29425.1-3 533-4 60823.3 -6 760 BUSINESS PERFORMANCE IN JANUARY–SEPTEMBER 2020 Savosolar’s revenue for January–September increased by 108.5 per cent and amounted to EUR 3.7 million (January–September 2019: EUR 1.8 million). The revenue for July–September increased by 1 624 per cent and amounted to EUR 1.7 (0.1) million. The solar thermal system and heat storage delivered to Fernwärme Ettenheim, Germany, were commissioned in July and handed over to the client after the reporting period in October. The value of the system is EUR 0.8 million, and it was Savosolar’s first delivery to Germany. The handover of the solar thermal system to Kyotherm Solar in Issoudun, France, is estimated to take place by the end of this year. The solar thermal system in Creutzwald, France, will also be handed over to the client during 2020. Savosolar’s operating result (EBIT) for January–September 2020 amounted to EUR -2.6 (-3.6) million. The result for January–September was EUR -3.5 (-4.6) million. The third quarter operating result was EUR -0.8 (-1.3) million and the result EUR -1.0 (-1.3) million. The favourable development of business performance was due to the growth in sales as well as the development measured taken to improve internal efficiency and the savings attained in personnel costs. Owing to the Covid pandemic, the company laid off on temporary basis 22 people on a part-time or full-time basis in April–June following the completion of the statutory co-operation negotiations. Additionally, in September, the company decided to lay off 21 people for a maximum of 90 days. At the end of September, Savosolar had 35 employees. Overall, the company calculates that it will achieve approximately EUR 0.2 million in savings by the end of 2020 through the temporary layoffs and the management salary reductions decided in the third quarter. The French company Sunti SAS has alleged that Savosolar has acted against the exclusive rights clause in the contract between the two companies and claims for a total compensation of approximately EUR 2.0 million from Savosolar. The first oral hearing between the parties before the commercial court of justice in Montpellier will be held on 9 November 2020. As already stated earlier, Savosolar considers Sunti’s claim for alleged breach of contract and claim for compensation to be without any merit. SIGNIFICANT EVENTS AFTER THE REPORTING PERIOD On 14 October 2020, Savosolar announced having signed a cooperation agreement on the representation of its products with a Polish company named Eko Ekon. On 21 October 2020, Savosolar announced having signed a cooperation agreement with Citrinsolar GmbH on the sale and delivery of large solar thermal systems in Germany. SAVOSOLAR PLC Board of Directors More information: CEO Jari Varjotie Phone: +358 400 419 734 E-mail: firstname.lastname@example.org Savosolar in brief Savosolar with its highly efficient collectors and large-scale solar thermal systems has taken solar thermal technology to the next level. The company’s collectors are equipped with the patented nano-coated direct flow absorbers, and with this leading technology, Savosolar helps its customers to produce competitive clean energy. Savosolar’s vision is to be the first-choice supplier to high performance solar installations on a global scale. Focus is on large-scale applications like district heating, industrial process heating and real estate systems – market segments with a big potential for rapid growth. The company primarily delivers complete systems from design to installation, using the best local partners. Savosolar is known as the most innovative company in the business and aims to stay as such. Savosolar's shares are listed on Nasdaq First North Growth Market Sweden with the ticker SAVOS and on Nasdaq First North Growth Market Finland with the ticker SAVOH. www.savosolar.com. The Company’s Certified Adviser is Augment Partners AB, email@example.com, tel. +46 8 505 65 172. Attachment Savosolar Plc_ Q3 2020 Business review 2020-10-26
Jobmaker will create just 10% 'genuinely additional' jobs of Coalition's total pledge, treasury says. Department estimates 45,000 jobs out of the government’s previously boasted 450,000 will actually be created by the youth hiring credit
A woman has been arrested on suspicion of murder after a man was found stabbed to death in a property in Croydon.Police were called by paramedics to a residential address on Clyde Road to reports of a stabbing at 7.40am on Sunday, October 25.
The veteran presenter was a household name throughout the 60s, 70s and 80s.
Bayer <BAYGn.DE> agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses. Germany's Bayer will pay $2 billion upfront and up to an additional $2 billion in milestone payments contingent on development achievements, it said on Monday. The North Carolina-based takeover target, also known as AskBio, is trying to use the harmless adeno-associated virus as a delivery device to bring genetic repair kits against a range of diseases into the body.Drugs and farming pesticides maker Bayer needs to upgrade its drug development pipeline amid a weaker outlook for agricultural sales and as it seeks to finalise an $11 billion settlement over claims its Roundup weedkiller causes cancer.
The Ministry of Health (MOH) confirmed three new COVID-19 cases in Singapore as of Monday (26 October) noon, taking its total case count to 57,973.
Nicola Adams and Katya Jones took to the floor for a quickstep
Wild hing makes India’s heart sing as favourite spice is home-grown at last. Asafoetida is a mainstay of the country’s cuisine, but only now are the first saplings being planted on Indian soil
UPPSALA, SWEDEN – LIDDS AB (publ) announces that intratumoral injection of NZ-TLR9, NanoZolid (NZ) formulation of a Toll-Like Receptor 9 (TLR9), results in strong antitumoral efficacy combined with prominent antitumoral immune responses in mouse tumor models. NZ-TLR9 forms an intratumoral depot which releases the TLR9 agonist for least 6 weeks and thus minimizes the need for repeated injections. Furthermore, we have identified both intratumoral- and plasma biomarkers needed to measure the activity of NZ-TLR9 in clinical trials. LIDDS has completed a preclinical data package using a TLR9 agonist formulated with NanoZolid®(NZ-TLR9) showing that a single NZ-TLR9 injection is reducing tumor growth and improves the survival of mice, with increase of intratumoral cytotoxic T- cells and activated dendritic cells. The TLR9 agonist is released during at least 6 weeks with equal in vivo efficacy which minimizes the need for repeated injections, which are needed when using standard formulated TLR9 agonists. In addition, the study also identified plasma biomarkers which are suitable to measure the biological activity of NZ-TLR9 in coming clinical trial. -I’m really happy to see our convincing preclinical data package with NanoZolid formulated TLR9, especially the six weeks of controlled release with strong anti-tumor effect. The results indicate that NanoZolid technology®, with controlled and sustained drug release, can be used to treat deep lying cancer tumors. These tumors are not suitable to be treated with standard TLR9 due to the necessity of weekly injections. The planning for a Phase I study treating solid tumors with intratumoral NZ-TLR9 is ongoing and we plan to start the study towards the second half of 2021, commented Monica Wallter, CEO of LIDDS. About TLRs and TLR9Toll-like receptors (TLRs) are key targets in the search for new treatments against cancer. TLRs are expressed on various immune cells, including dendritic cells, and upon activation they initiate the body’s immune response. TLR9 activation leads to an immunologically active tumor environment with recruitment of the cytotoxic T cells which are necessary for an antitumor response in immunotherapy. Thus, TLR9 agonists can convert immunologically “cold” tumors to immunologically “hot” tumors. The most promising target cancers for the TLR9 project are head and neck cancer, prostate cancer, sarcomas and lymphomas. These malignancies are diagnosed in around 2 million patients each year. The market for TLR agonists is expected to be worth hundreds of millions of dollars over the coming years. For additional information, please contact: Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, firstname.lastname@example.org This information is such that LIDDS AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above on October 26, 2020 at 08:30 CET. LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, email@example.com, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.
Good morning, Please find below the press release issued today. Best regards, Florence LièvreGlobal PR Manager | Group Marketing & Communications Capgemini Group | ParisTel.: +33 1 47 54 50 71Email : firstname.lastname@example.org_____________________ Press contact:Sam ConnattyTel: +44 370 904 3601 E-mail: email@example.com ‘Get the future you want’ Capgemini launches a new brand promise that conveys the spirit of the Group to its clients and communities Paris, October 26 2020 – Capgemini launches today a bold and active brand platform for its clients and its communities: “Get the future you want.” The new brand platform reflects the zeitgeist of current times where world events and rapid digital transformation require people to look at how they can leverage technology to define the future they want, a future that is inclusive and sustainable. “Our new brand platform is more than a tagline. It captures the spirit and energy of Capgemini and conveys our optimistic vision of the future,” comments Aiman Ezzat, CEO of the Capgemini Group. “We are conscious that technology is now the critical enabler to almost every transformation of business and society. However, with this potential comes a great responsibility to leverage it in a human way to energize people and businesses. Our clients need to know that they have a business partner at their side, to help them define their future through technology and make it a reality. For our team members, we help them to define their careers and achieve their personal objectives. That is our focus; to help our clients, our people, and our communities get the future they want.” ’Get the future you want’ appeals to organizations looking for a business partner they can trust, as much as it does to those who want to work for a responsible organization that empowers them. It builds on what Capgemini is recognized for today: its business and industry relevance, its deep and long-term technology experience and its passion for people. It also gives visibility to the Group’s commitment to inclusiveness and sustainability. A versatile brand platformVirginie Regis, Chief Marketing and Communications Officer and member of the Group Executive Committee at Capgemini explains, “Our new brand platform captures the spirit of our people. The planned creatives will demonstrate Capgemini’s ability to understand the key challenges its clients are facing - from the role of technology in their business to the impact they have on the environment. Through our global advertising campaign and integrated communication activities we want our teams, our clients, and our partners, to feel that change can happen the way they want it to, and that we will help them achieve it.” In further development, this platform will showcase Capgemini’s industry leadership in advancing the digital consumer experience, accelerating intelligent industry and transforming enterprise efficiency, leveraging its deep expertise in cloud and data. The expression of the brand promise will be represented across a variety of media platforms to reach Capgemini’s target market of CxOs and top talent, each and every time with people at its heart. It will be featured in two waves, firstly in a global advertising campaign on CNBC up until the end of the year, complemented by targeted promotion across social media platforms. This will then be augmented by a series of high-profile homepage takeovers in leading media within Capgemini’s key geographies throughout November. To find out more and experience the ‘Get the future you want’ creative assets visit: https://www.capgemini.com/resources/get-the-future-you-want Note to Editors:Hi-resolution images and video of the new brand platform creatives are available on request. About CapgeminiCapgemini is a global leader in consulting, digital transformation, technology, and engineering services. The Group is at the forefront of innovation to address the entire breadth of clients’ opportunities in the evolving world of cloud, digital and platforms. Building on its strong 50-year heritage and deep industry-specific expertise, Capgemini enables organizations to realize their business ambitions through an array of services from strategy to operations. A responsible and multicultural company of 265,000 people in nearly 50 countries, Capgemini’s purpose is to unleash human energy through technology for an inclusive and sustainable future. With Altran, the Group reported 2019 combined global revenues of €17 billion. Visit us at www.capgemini.com. Attachment 2020_10_26_Capgemini_Get the future you want
Bayer AG today announced the acquisition of Asklepios BioPharmaceutical, Inc. (AskBio), a US-headquartered biopharmaceutical company specialized in the research, development and manufacturing of gene therapies across different therapeutic areas. AskBio’s development portfolio includes investigational pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases.
Harry Styles is investing in a new arena to be built in his hometown of Manchester. Dubbed "Co-op Live," the Oak View Group (OVG) is leading the effort to construct the venue, which gained planning approval in September and is set to open in 2023. Its arrival represents a £350m investment in the city and […]
Press release Hørsholm, Denmark (26 October 2020) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance to the Company for three new DRP® biomarker patents in conjunction with use of several of its clinical pipeline drugs. The USPTO has issued Notices of Allowance to the Company on the following three patent applications: U.S. Patent Application No.: 16/444,881, “METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS” – Directed to a DRP® biomarker for the Company’s cancer drug Dovitinib, which biomarker is in development by Company as a companion diagnostic to select high likely responders for Dovitinib.U.S. Patent Application No.: 15/858,703, “METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS” – Directed to a DRP® biomarker for Cisplatin, including the Company’s cancer drug LiPlaCis®, which biomarker is in development by Company as a companion diagnostic to select high likely responders for LiPlaCis®.U.S. Patent Application No.: 15/978,655, “METHODS FOR PREDICTING DRUG RESPONSIVENESS IN CANCER PATIENTS” – Directed to DRP® biomarkers for anthracyclines, including doxorubicin, epirubicin, and the Company’s cancer drug 2X-111, which biomarker is in partnered development by Smerud Medical Research International as a companion diagnostic to select high likely responders for 2X-111. The allowance and imminent issuance of these three new DRP® biomarker patents further expands Allarity’s patent portfolio on unique, drug-specific DRP® biomarkers developed with its best-in-class and highly validated DRP® platform technology. The Company has now gained allowance and/or issuance of patents on more than 60 different DRP® biomarkers. Dovitinib, originally developed by Novartis, addresses a significant unmet need for improved therapies for the treatment of renal cell carcinoma and is a potential therapeutic alternative to sorafenib. Allarity is currently preparing to file its first new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval of dovitinib as a treatment for renal cell carcinoma (RCC), using its Dovitinib DRP® as a companion diagnostic to select and treat high likely responder patients. Dovitinib also has promising potential as a monotherapy in a number of other indications, including metastatic estrogen receptor (ER) positive breast cancer, hepatocellular cancer, endometrial cancer and gastrointestinal stromal tumors, as well as in combination therapy with other approved drugs, including immune checkpoint inhibitors. LiPlaCis® is an advanced, targeted liposomal formulation of cisplatin, one of the world’s most widely used chemotherapies, being developed in partnership with Smerud Medical Research International AS for the treatment of metastatic breast cancer, using the Cisplatin DRP® as a companion diagnostic to select and treat high likely responder patients. The specific LiPlaCis® formulation allows delivery of the drug directly at tumor site, thereby increasing drug targeting at the tumor and reducing negative, off-target drug effects. LiPlaCis® has previously shown promising results in a Phase 2 study in DRP®-selected patients with late-stage metastatic breast cancer (mBC). In August 2019, the U.S. FDA approved an investigational device exemption (IDE) application for use of the Company’s LiPlaCis® DRP® companion diagnostic in a planned pivotal Phase 3 study in mBC. 2X-111 is an advanced, targeted liposomal formulation of doxorubicin, one of the world’s most widely used chemotherapies, being developed in partnership with Smerud Medical Research International AS for the treatment of glioblastoma multiforme (GBM), using the Doxorubicin DRP® as a companion diagnostic to select and treat high likely responder patients. The specific 2X-111 formulation allows delivery of the drug across the blood-brain barrier (BBB) directly at the brain tumor site, thereby increasing drug targeting at the tumor and reducing negative, off-target drug effects. 2X-111 has previously shown promising results in a Phase 2 study in both GBM patients and patients with brain metastases of breast cancer. Steve Carchedi, CEO of the Company, noted “We see the allowance of these patents from the USPTO as further validation of the inventive importance of our core DRP® platform and its resulting, drug-specific companion diagnostics, which we believe will help bring the promise of personalized medicine to cancer patients. The issuance of these new patents on our dovitinib, LiPlaCis®, and 2X-111 programs solidifies our competitive advantage as we advance these promising cancer therapeutics to the market and to patients, and underscores our global leadership in the development and use of best-in-class companion diagnostics that are designed to match the right cancer patient to the right drug.” Steen Knudsen, Ph.D., CSO and Co-Founder of the Company, further stated, “I am pleased to see the USPTO’s recognition of these three novel and valuable DRP® biomarkers, through allowance of these patents, as Allarity continues to develop and utilize such DRP® biomarkers as companion diagnostics to advance our therapeutic pipeline, including dovitinib, LiPlaCis®, and 2X-111 towards approval and to improve treatment options for cancer patients.” About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. DRP® is based on messenger RNA from the patient’s biopsies. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs. About Allarity Therapeutics Allarity Therapeutics (Nasdaq First North Growth Market Stockholm: ALLR.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, the DRP® platform. The company has a mature portfolio of six drug candidates, including compounds in the pre-registration stage. The product portfolio includes: Stenoparib (2X-121), a PARP inhibitor in Phase 2 for ovarian cancer; Dovitinib, a pan-TKI in post-Phase 3 for renal cell carcinoma; IXEMPRA® (Ixabepilone), a microtubulin inhibitor approved in the U.S. for the treatment of breast cancer; LiPlaCis®, a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; and Irofulven, a DNA damaging agent in Phase 2 for prostate cancer. Follow us on social media: Facebook: https://www.facebook.com/AllarityTx/ LinkedIn: https://www.linkedin.com/company/allaritytx/ Twitter: https://twitter.com/allaritytx Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Allarity’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Allarity’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Allarity undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. ### Media Contacts: Europe: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 firstname.lastname@example.org U.S. Mike Beyer Sam Brown Inc. +1 312-961-2502 email@example.com Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Email: firstname.lastname@example.org. Tel: +46 11 32 30 732 This information is information that Allarity A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on 26 October 2020. Attachment New DRP Patents Allowed Oct 2020
The coronavirus test will be available through the retailer within weeks, it was reported.
Police said all 22 crew members were safe and well.
France may be experiencing 100,000 new COVID-19 cases per day -- twice the latest official figure -- Professor Jean-François Delfraissy, who heads the scientific council that advises the government on the pandemic, told RTL radio on Monday. France, the euro zone's second-biggest economy, is currently examining whether to tighten lockdown measures further to curb the resurgence of the COVID-19 virus, having already imposed night-time curfews on major cities including Paris.
Asian markets mostly fell Monday with traders increasingly pessimistic that US lawmakers will pass a new stimulus package before next week's election, while spiking virus cases fanned worries about the economic impact of new containment measures.